Skip to main content
SpringerLink
Log in

Anti-HCV therapy worth it in Italy, with initial investment costs recouped after around 4 years

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Marcellusi A, et al. Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis. Applied Health Economics and Health Policy : 12 Oct 2021. Available from: URL: http://doi.org/10.1007/s40258-021-00677-x

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-HCV therapy worth it in Italy, with initial investment costs recouped after around 4 years. PharmacoEcon Outcomes News 890, 2 (2021). https://doi.org/10.1007/s40274-021-08125-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08125-0

Search

Navigation